Analysis of substrate specificity and cyclin Y binding of PCTAIRE-1 kinase  by Shehata, Saifeldin N. et al.
Cellular Signalling 24 (2012) 2085–2094
Contents lists available at SciVerse ScienceDirect
Cellular Signalling
j ourna l homepage: www.e lsev ie r .com/ locate /ce l l s igAnalysis of substrate speciﬁcity and cyclin Y binding of PCTAIRE-1 kinase
Saifeldin N. Shehata a, Roger W. Hunter a,1, Eriko Ohta a, Mark W. Peggie a, Hua Jane Lou b, Frank Sicheri c,
Elton Zeqiraj c, Benjamin E. Turk b, Kei Sakamoto a,⁎,1
a MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
b Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, CT 06520, USA
c Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5Abbreviations: CDK, cyclin-dependent protein kinase; N
factor; GST, glutathione S-transferase; HA, haemagglutin
PSPL, positional scanning peptide library.
⁎ Corresponding author at: Nestlé Institute of Healt
Quartier de l'innovation, bâtiment G, 1015 Lausan
216326133; fax: +41 216326499.
E-mail address: Kei.Sakamoto@rd.nestle.com (K. Sak
1 Current address: Nestlé Institute of Health Sciences
l'innovation, bâtiment G, 1015 Lausanne, Switzerland.
0898-6568 © 2012 Elsevier Inc.
doi:10.1016/j.cellsig.2012.06.018
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 8 June 2012
Accepted 25 June 2012
Available online 11 July 2012
Keywords:
Cyclin-dependent kinase
CDK16
PCTK1
Cell cycle
Positional scanning peptide library
Proline-directed kinasePCTAIRE-1 (cyclin-dependent kinase [CDK] 16) is a highly conserved serine/threonine kinase that belongs to
the CDK family of protein kinases. Little is known regarding PCTAIRE-1 regulation and function and no robust
assay exists to assess PCTAIRE-1 activity mainly due to a lack of information regarding its preferred consensus
motif and the lack of bona ﬁde substrates. We used positional scanning peptide library technology and iden-
tiﬁed the substrate-speciﬁcity requirements of PCTAIRE-1 and subsequently elaborated a peptide substrate
termed PCTAIRE-tide. Recombinant PCTAIRE-1 displayed vastly improved enzyme kinetics on PCTAIRE-tide
compared to a widely used generic CDK substrate peptide. PCTAIRE-tide also greatly improved detection of
endogenous PCTAIRE-1 activity. Similar to other CDKs, PCTAIRE-1 requires a proline residue immediately
C-terminal to the phosphoacceptor site (+1) for optimal activity. PCTAIRE-1 has a unique preference for a
basic residue at +4, but not at +3 position (a key characteristic for CDKs). We also demonstrate that
PCTAIRE-1 binds to a novel cyclin family member, cyclin Y, which increased PCTAIRE-1 activity towards
PCTAIRE-tide >100-fold. We hypothesised that cyclin Y binds and activates PCTAIRE-1 in a way similar to
which cyclin A2 binds and activates CDK2. Point mutants of cyclin Y predicted to disrupt PCTAIRE-1-cyclin
Y binding severely prevented complex formation and activation of PCTAIRE-1. We have identiﬁed
PCTAIRE-tide as a powerful tool to study the regulation of PCTAIRE-1. Our understanding of the molecular
interaction between PCTAIRE-1 and cyclin Y further facilitates future investigation of the functions of
PCTAIRE-1 kinase.
© 2012 Elsevier Inc. Open access under CC BY license.1. Introduction
The human CDK16 gene, which encodes PCTAIRE-1, maps to the X
chromosome (Xp11.3–p11.23), a chromosomal region associated
with a growing number of diseases including neurodegenerative dis-
orders with a genetic basis [1]. PCTAIRE-1 belongs to the CMGC pro-
tein kinase family [2], which includes Cyclin-dependent kinases
(CDK), Mitogen-activated protein kinases, Glycogen synthase kinase
and CDK-like kinases, and is one of three members of the PCTAIRE
family (namely PCTAIRE-1, -2 and ‐3). PCTAIRE proteins comprise
three principal domains: a central kinase domain that is highly con-
served between the three isoforms (~80% protein sequence identity),
ﬂanked by a long N-terminus and a short C-terminus that are uniqueSF, N-ethylmaleimide-sensitive
in; MBP, myelin basic protein;
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 license.for each isoform [3]. The kinase domain of PCTAIREs is closely related
to that of other conventional CDKs (e.g. PCTAIRE-1 shares 53.5% se-
quence identity with CDK2). The CDK family members contain a high-
ly conserved PSTAIRE motif, which plays a key role in cyclin binding,
and the interaction between CDKs and cyclins is essential for maxi-
mum CDK catalytic activity [4]. As PCTAIREs have retained this impor-
tant protein-protein interaction motif (albeit the serine residue has
been exchanged for cysteine) they are classiﬁed into a subgroup of
the CDK family, which includes mammalian PFTAIRE, PCTAIRE,
PITSLRE, PISSLRE, and more [2].
Because of the well conserved primary sequence between
PCTAIRE-1 and CDKs and established roles of CDKs in cell cycle regu-
lation, it was originally hypothesised that PCTAIRE-1 might also be
involved in cell cycle control. In support of this, one study demon-
strated that endogenous PCTAIRE-1 activity was low during G1 and
G1-S phases of the cell cycle, but increased during S and G2 phases
[5]. In contrast, other studies showed that PCTAIRE-1 function was
not associated with the cell cycle (reviewed in [3]). For example,
overexpression of PCTAIRE-1 in neuroblastoma cells had no effect
on their cell cycle progression [6]. Therefore, any involvement of
PCTAIRE-1 in cell cycle regulation is debatable based on current evi-
dence. Moreover, it is acknowledged that PCTAIRE-1 is expressed in
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abundance in brain and testis [7,8]. This suggests that its function is
not restricted, if at all involved, with the regulation of proliferation/cell
cycle. In line with this notion, PCTAIRE-1 has been variously associated
with other functions such as, vesicle trafﬁcking [9–11], neurite out-
growth [6], and spermatogenesis [12].
Although PCTAIRE-1 is implicated in a variety of cellular processes,
knowledge about its regulation remains elusive. No bona ﬁde sub-
strates for PCTAIRE-1 have been identiﬁed, and the phosphorylation
consensus sequence is unknown, severely limiting current methods
to measure PCTAIRE-1 activity. Currently, recombinant and endoge-
nous PCTAIRE-1 isolated from cell/tissue extracts are assayed using
generic kinase substrates such as Myelin Basic Protein (MBP) and his-
tone H1 [5–7,10,13]. However, the use of such generic substrates often
causes major problems in detecting activity of a particular kinase from
cell/tissue extracts by immunoprecipitation, because of confounding ac-
tivity from inevitable contaminating kinaseswhich renders data interpre-
tation difﬁcult and uncertain. Several members of the CDK family
(e.g. CDK2, CDK5) prefer to phosphorylate serine or threonine residues
followed by a proline residue and having a basic residue (K/R/H) at
the +3 position (e.g. S/T-P-X-K/R/H, where X represents any
amino acid) [14,15]. Therefore, it is predicted, although not yet test-
ed, that PCTAIRE-1 might have the same substrate requirements. In
line with this notion, it has been reported that PCTAIRE-1 phosphor-
ylates N-ethylmaleimide-sensitive factor (NSF, a vesicular transport
protein that regulates protein exocytosis) at Ser569, which lies with-
in an optimal consensus sequence for conventional CDKs (S*–P–X–R,
* represents the phosphorylated residue and X represents any amino
acid) [10].
To gain insights into PCTAIRE-1 substrate speciﬁcity, we took ad-
vantage of positional scanning peptide library technology [16]. We
have identiﬁed that PCTAIRE-1 has a unique substrate-preference
compared to other CDK members and developed a novel peptide sub-
strate termed “PCTAIRE-tide”. Recombinant PCTAIRE-1 displayed vastly
improved enzyme kinetics against PCTAIRE-tide compared to a widely
used generic CDK substrate peptide. More importantly, PCTAIRE-tide
enabled the unambiguous detection of endogenous PCTAIRE-1 activity.
Recent studies have proposed a possible PCTAIRE-1 activating subunit.
Ou et al. [17] showed that the Caenorhabditis elegans homologue of
PCTAIRE-1, PCT1, bound to CYY1, the C. elegans homologue of human
cyclin Y. Moreover, while ourmanuscript was in preparation, Mikolcevic
et al. have conﬁrmed that mammalian PCTAIRE-1 also interacts with
cyclin Y [12]. Here we demonstrate that binding of PCTAIRE-1 to cyclin
Y increases (>100-fold) PCTAIRE-1 activity towards PCTAIRE-tide. We
have also shed light onto the molecular basis of PCTAIRE-1–cyclin Y
interaction and provide a model by which cyclin Y activates PCTAIRE-1.
Our structural analysis and mutagenesis data suggest that cyclin Y
binds and activates PCTAIRE-1 in amanner reminiscent of the activating
interaction between cyclin A2 and CDK2.2. Materials and methods
2.1. Materials
PCTAIRE-1C-16 (sc-174) and PCTAIRE-1G6.1 (sc-53410) antibodies
were from Santa Cruz Biotechnology. Cyclin Y antibody was from
Proteintech. HA.11 (16B2) antibody was from Covance Research Prod-
ucts. The following antibodies were raised in sheep by the Division of
Signal Transduction Therapy (DSTT, University of Dundee) against the
indicated immunogens: PCTAIRE-1 (S552C, full length human
6×his-PCTAIRE-1), cyclin Y (S206D, full length human GST-cyclin Y).
rCDK2–cyclin A2 was prepared by overexpression in Escherichia coli
as previously described [18]. Peptide substrates for kinase assays were
synthesised by GL Biochem, and the peptide library was synthesised
by Anaspec, Inc. [γ-32P] ATP was from PerkinElmer. HRP-conjugatedsecondary antibodies were from Jackson Immunoresearch. Unless oth-
erwise indicated all other reagents were from Sigma.
2.2. Cloning and mutagenesis
All plasmid constructs were generated and ampliﬁed using stan-
dard molecular biology techniques. PCTAIRE-1 (NCBI reference
NP_006192.1) was ampliﬁed from IMAGE EST 3504276 using KOD
Hot Start DNA Polymerase (Novagen). The resulting PCR fragment
was cloned into pSC-b (Agilent) and sequence veriﬁed. The insert
was excised using Not1 and ligated into the same site in pEBG6P
and pCMVFLAG-2. Cyclin Y (NP_659449.3) was ampliﬁed from IMAGE
EST 6340750 as described above and then cloned into the BamHI and
Not1 sites in pCMVHA-1. All mutageneses were carried out following
the Quick Change method (Agilent) but using KOD Hot Start DNA Poly-
merase. Cloning of Nuak1 was described previously [19].
2.3. Cell culture, transfection and harvesting
Human embryonic kidney (HEK) 293 cells were maintained in
high glucose DMEM supplemented with 10% (v/v) foetal bovine serum
under 5% CO2. Cells were transfected with DNA using polyethylenimine
[20] and harvested 36 h post-transfection. Cells were washed with
ice-cold PBS and scraped into 50 mM Tris–HCl pH 7.5, 1 mM EDTA,
1 mM EGTA, 0.27 M sucrose, 1% (w/v) Triton X-100, 50 mM NaF,
5 mM Na4P2O7, 1 mM Na3VO4, 1 mM dithiothreitol (DTT), 1 mM
benzamidine and 0.5 mM PMSF. Lysates were clariﬁed at 20,000g for
10 min at 4 °C and stored at−80 °C. Protein concentration was deter-
mined using Bradford reagent and BSA standard.
2.4. Preparation of GST–PCTAIRE-1
HEK293 cells were transfected with pEBG6P encoding GST-tagged
human PCTAIRE-1 and harvested 36 h later as described above. GST–
PCTAIRE-1 was isolated by batch-wise puriﬁcation using Glutathione-
Sepharose 4B. Brieﬂy, lysates were incubated with equilibrated resin
for 1 h at 4 °C, washed extensively with lysis buffer and eluted with
20 mM reduced glutathione in 50 mM Tris–HCl pH 8, 0.27 M sucrose,
0.1 mM EGTA and 1 mM DTT. Protein concentration was estimated
by densitometry of Coomassie-stained gels using BSA standards.
PCTAIRE-1 preparations were snap-frozen in N2(l) and stored at
−80 °C.
2.5. Positional scanning peptide library screen (PSPL)
PSPL screening was performed as previously described [21]. Brieﬂy,
peptides had the sequence Y-A-X-X-X-X-X-S/T-X-X-X-X-A-G-K-K-
(biotin), where X is generally an equimolar mixture of the 17 amino
acid residues excluding Cys, Ser and Thr. For each peptide in the set, a
single X residue was ﬁxed as one of the 20 unmodiﬁed amino acids,
phosphothreonine or phosphotyrosine. Aliquots of peptides (0.6 mM)
were transferred from a 1536-well stock plate to a 1536-well reaction
plate containing 2 μl reaction buffer (50 mM HEPES, pH 7.4, 1 mM
EGTA, 1 mM DTT, 10 mM Mg(OAc)2, 0.1% Tween 20) in each well
using a pin tool equipped with 200 nl stainless steel slot pins (V&P
Scientiﬁc). Kinase (75 μg of puriﬁed WT- or KD-GST–PCTAIRE-1
[Fig. 1B] or 3.75 μg of WT- or KD-FLAG–PCTAIRE-1–cyclin Y complex
[Fig. 4C]), rabbit protein kinase inhibitor (PKI, 0.5 μM) and radiolabelled
ATP (50 μM, 0.33 μCi/μl [γ-33P]ATP) were added together to each well
using a strip of 200 nl slot pins, and the plate was sealed and incubated
at 30 °C for 2 h. Aliquots (200 nl) were then transferred using a pin
tool to a streptavidin membrane, which was washed twice with 0.1%
SDS in TBS (10 mM Tris, pH 7.5, 140 mM NaCl), twice with 2 M NaCl,
and twice with 1% H3PO4 in 2 M NaCl. The membrane was then air
dried and exposed to a phosphor storage screen to visualise radiolabel
incorporation.
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Fig. 1. Determination of PCTAIRE-1 optimal substrate motif. (A) GST–PCTAIRE-1 WT and kinase dead (KD, D304A) were prepared by overexpression in HEK293 and 1 μg assayed in
vitro for phosphotransferase activity against 250 μM of the canonical CDK substrate (CDK-tide, PKT*PKKAKKL) or a peptide derived from the putative PCTAIRE-1 substrate, NSF
(NSF-tide, FIKICS*PDKMIGRRR) as described in Materials and methods. (B) GST–PCTAIRE-1 WT/KD was prepared as described in (A) and the optimal substrate motif determined
by positional scanning peptide library screening (PSPL) as described in Materials and methods. (C) The activity of GST–PCTAIRE-1 (1 μg) and CDK2–cyclin A2 (10 ng) was assayed
against a panel of CDK-tide derivatives (concentration ﬁxed at 250 μM) based on the results of the degenerate library screen (modiﬁcations are underlined). Results are expressed
as mean±SEM and are representative of 3 independent experiments.
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Animal studies were approved by the University of Dundee Ethics
Committee and performed under a UK Home Ofﬁce project license.
C57BL/6J mice were obtained from Harlan (Leicestershire, UK). Mice
were killed by cervical dislocation and tissues rapidly dissected and fro-
zen in N2(l). Tissueswere homogenised using a rotor-stator homogeniser
(Polytron, Kinematica AG) in lysis buffer, clariﬁed at 13,000g for 10 min
at 4 °C and stored at −80 °C. Protein concentration was determined
using Bradford reagent and BSA as a standard.
2.7. Immunoprecipitation
Cell/tissue lysates were incubated with 1–2 μg antibody (anti-
PCTAIRE-1 G6.1 or anti-cyclin Y S206D) and 5 μl protein G-Sepharose
for 1 h at 4 °C. FLAG- and HA-tagged proteins were isolated using 5 μl
FLAG M2- or HA-agarose respectively. Immune complexes were
pelleted at 500g for 1 min and washed 2× 0.5 ml lysis buffer+0.15 M
NaCl, 2× Buffer A (50 mM tris pH 8, 0.1 mM EGTA, 1 mM DTT) and
eluted with Laemmli sample buffer for analysis by immunoblotting or
assayed directly for kinase activity.
2.8. Western blotting
Cell/tissue lysates were denatured in Laemmli buffer, separated by
tris-glycine SDS-PAGE and transferred to PVDF membrane. Mem-
branes were blocked for 1 h in 20 mM Tris–HCl (pH 7.6), 137 mM
NaCl, 0.1% (v/v) Tween-20 (TBST) containing 5% (w/v) skimmed
milk. Membranes were incubated in primary antibody prepared
in TBST containing 5% (w/v) BSA overnight at 4 °C. Detection was
performed using HRP-conjugated secondary antibodies and enhanced
chemiluminescent reagent.2.9. Kinase assay
Puriﬁed rPCTAIRE-1, rCDK2–cyclin A2 or immune complexes iso-
lated from cell/tissue lysates were assayed for phosphotransferase
activity in a ﬁnal assay volume of 50 μl containing 50 mM HEPES pH
7.5, 0.1 mM EGTA, 10 mM Mg(OAc)2, 0.1 mM [γ-32P] ATP (300 CPM
pmol−1), 1 mM DTT and the indicated concentrations of peptide sub-
strate. Reactions were incubated at 30 °C and terminated by spotting
onto P81 paper and immersion in 75 mM H3PO4. P81 ﬁlters were
washed 3× 10 min with H3PO4, rinsed with acetone, air-dried and
incorporation of [γ-32P] determined by Cherenkov counting. Results
are expressed in U mg−1, where 1 U is deﬁned as the incorporation
of 1 nmol phosphate.min−1.
3. Results
3.1. Puriﬁed PCTAIRE-1 poorly phosphorylates the generic CDK substrate
peptide
PCTAIRE isoforms are closely related in primary sequence to other
members of the cyclin-dependent kinase (CDK) family, including the
most widely studied, CDK2. Since many of the CDK family members
(e.g. CDK2) prefer to phosphorylate proline-directed serine/threonine
residues followed by a basic residue at the +3 position (consensus
S/T*–P–X–K/R [S/T* represents the phosphorylated residue and X
represents any amino acid]), we speculated that PCTAIRE-1 might
exhibit similar properties. To test this, we assayed the kinase activity
of puriﬁed GST-tagged PCTAIRE-1 wild-type (WT) and a control
kinase-dead/inactive (KD) mutant (in which Asp304 in the Mg2+
binding DFG-motif was substituted to Ala [D304A]), using two peptides
conforming to the CDK consensus motif. One substrate has an amino
acid sequence of PKT*PKKAKKL, known as CDK substrate peptide, as it
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histone H1. The other, termed “NSF-tide”, has an amino acid sequence
of FIKICS*PDKMIGRRR derived from the surrounding sequence of
the reported PCTAIRE-1 phosphorylation site (Ser569) [10] from NSF
protein (residues 564 to 575 of human NSF, with an additional three
Arg residues at the C-terminal to ensure proper binding to P81 paper).
As shown in Fig. 1A, we observed that when using near saturating con-
centrations (250 μM) of both substrates, PCTAIRE-1WT showed similar
activity towards these two substrates, and this kinase activity was sig-
niﬁcantly higher than that measured from PCTAIRE-1 KD. However,
the speciﬁc activity towards CDK substrate peptide by PCTAIRE-1 was
vastly lower (>2000-fold, data not shown) compared to that produced
by CDK2–cyclin A2 (expressed and puriﬁed from E. coli). It could be ar-
gued that PCTAIRE-1 isolated from HEK293 cells had only partial activ-
ity (possibly due to the absence of activating and/or presence of
inhibitory factors), or that the substrate sequences were suboptimal
for PCTAIRE-1 activity.
3.2. Analysis of substrate speciﬁcity of PCTAIRE-1 by a positional
scanning peptide library screening (PSPL) approach
Since the optimal phosphorylation consensus for PCTAIRE-1 has not
been determined, we have utilised a PSPL [22] to identify an optimal
PCTAIRE-1 phospho-peptide. This assay utilised an arrayed library of
198 biotinylated peptide mixtures in which each amino acid residue is
systematically substituted at each of 9 positions within the peptide se-
quence. Recombinant WT-PCTAIRE-1 or KD-PCTAIRE-1, isolated from
HEK293 cells, was employed to phosphorylate all 198 peptides simulta-
neously in solution using radiolabeled ATP, and biotinylated peptides
were captured on a streptavidin-coated membrane. Radiolabel incorpo-
ration into each peptide was detected by phosphor imaging. As some-
what expected (based on similarity of kinase domain sequences
between PCTAIRE-1 and CDK2) the peptide scanning analysis identiﬁed
that PCTAIRE-1 had a strong preference for proline in the +1 position
relative to the phosphoacceptor site (Fig. 1B). Interestingly, we also ob-
served that PCTAIRE-1 preferentially phosphorylated peptides
containing basic residues at the+2position (His, Lys or Arg) and+4po-
sition (His, Lys and Arg), even though signal intensity was modest. We
also observed strong signals for peptides with Ser residues ﬁxed at
most positions. While this observation is likely to be an artefact arising
from the presence of two phosphorylatable sites in those peptides,
it does suggest that PCTAIRE-1 is likely to prefer Ser over Thr as the
phosphoacceptor residue. In addition, we also observed relatively strong
phosphorylation of peptides containingArg residues at both the ‐2 and ‐
3 positions. These Arg signals were also observed in experiments
performed with kinase-inactive PCTAIRE-1, indicating that they are
likely due to a contaminating kinase activity present in our preparations.
Similar results were also reported in previous studies employing recom-
binant kinase-inactive GST-IκB kinase-β [16] and also kinase-inactive
GST-LRRK2 kinase [23] both isolated from HEK293 cells. This trace
level of protein kinase activity probably results from kinases present
in HEK293 cells that contaminate the GST-tagged protein preparations.
To validate results from the peptide screen, we have obtained a set
of synthetic peptides, in which residues from +1 to +4 from the
phosphoacceptor Thr residue (of the parental CDK substrate peptide)
were substituted to various amino acids (mainly to non-charged [Ala]
or charged [Arg or Glu] amino acids), and compared the activity of
PCTAIRE-1 and CDK2–cyclin A2-complex against these peptides rela-
tive to the parental CDK substrate peptide. As predicted, kinase activ-
ity of both enzymes was abolished when the Pro residue at the +1
position was substituted to an Ala (+1P→A) (Fig. 1C). Substitution
of the Pro residue at the +1 position with Gly (+1P→G) produced
similar results (data not shown). When the peptide in which the
Lys at the +2 position was substituted to an Ala (+2K→A) was
used, activity of both kinases was robustly reduced. Furthermore,
PCTAIRE-1 activity was increased ~2-fold when the +4A→R peptidewas used, supporting the results obtained from the peptide library
screen (Fig. 1B). In contrast, activity of CDK2–cyclin A2 was compa-
rable towards CDK substrate peptide and the+4A→R peptide. Unex-
pectedly, PCTAIRE-1 activity showed a marked ~3-fold increase when
the +3K→A peptide was used. Coupled to this, was a signiﬁcant
decrease in CDK2–cyclin A2-complex activity to ~7-fold lower than its
activity on the original CDK substrate peptide when using +3K→A
peptide. Finally, the activity of both kinases against the +3K→E
peptide was negligible. Taken together, these results indicate that
PCTAIRE-1 has a strong preference for Pro in the+1 position relative
to the phosphoacceptor site and also prefers a non-charged amino
acid (e.g. Ala) at the +3 position, as both a charged basic (Lys) or
an acidic (Glu) residue in that position have a signiﬁcantly lower
kinase activity.
3.3. Development of an optimal PCTAIRE-1 substrate
We examined additional peptides to consider the potential pref-
erence of Ser as phosphoacceptor residue over Thr, a non-charged
amino acid (e.g. Ala) at the +3 position and positive charge at the
+4 position, by steady state kinetic analysis. The most preferred
PCTAIRE-1 substrate peptide was PKSPKARKKL (modiﬁed from the
parental PKTPKKAKKL CDK substrate peptide), which showed a Km
of ~4 μM and Vmax of ~550 mU mg−1 (Fig. 2A). This was followed
by SPKAA and TPKAA, which also exhibited relatively high substrate
afﬁnity (Km of ~25 μM and ~36 μM, respectively). The rest of the pep-
tides, including the parental CDK substrate, showed profoundly lower
or negligible afﬁnity for PCTAIRE-1. Regarding the substrate prefer-
ence for CDK2–cyclin A2, TPKKR, SPKKA and TPKKA peptides showed
the highest afﬁnity (Km of ~20 μM) and Vmax (~1100–1500 mUmg−1)
(Fig. 2B). The remaining peptides showed profoundly lower or negli-
gible afﬁnity, therefore reliable kinetic values (Km and Vmax) could not
be calculated.
To further elaborate and validate the substrate speciﬁcity of
PCTAIRE-1, we obtained an additional set of peptides in which resi-
dues from +2 to +4 of the original NSF-tide (FIKICSPDKMIGRRR)
were substituted to various amino acids, and performed kinetic analysis
using puriﬁed GST–PCTAIRE-1. As shown in Fig. 2C, the afﬁnity of
NSF-tide/SPDKM was negligible compared to any of the other peptides
tested, and substitution of the aspartic acid at the+2 position to a basic
lysine (SPKKM) signiﬁcantly increased its afﬁnity (Km of ~23 μM). This
was consistent with the peptide library screen (Fig. 1B) and kinetic anal-
ysis usingmodiﬁed CDK substrate peptides (Fig. 2A), and conﬁrmed that
PCTAIRE-1 does not preferentially phosphorylate peptideswith an acidic
residue in the +2 position from the phosphoacceptor Ser/Thr. It should
benoted that contrary towhatwe observedwith themodiﬁed CDK sub-
strate peptides, SPKKMhad higher afﬁnity than SPKAM, suggesting that
surrounding residues are likely to affect substrate afﬁnity. Finally,
Fig. 2C shows that, similar to the modiﬁed CDK substrate peptides,
the modiﬁed NSF-tide SPKAR peptide showed highest substrate afﬁnity
(Km of ~17 μM) and Vmax (~347 mU mg−1). Taken together, we found
that a peptide sequence of PKSPKARKKL is the optimal peptide sequence
for measuring recombinant PCTAIRE-1 activity in vitro and thus we
termed it “PCTAIRE-tide” (PCTAIRE kinase-tide).
3.4. PCTAIRE-tide substrate enables detection of endogenous PCTAIRE-1
activity
We next wished to validate if the PCTAIRE-tide substrate is an
improved tool for measuring endogenous PCTAIRE-1 activity. For
this purpose, endogenous PCTAIRE-1 was immunoprecipitated from
untransfected HEK293 cell extracts and kinase activity assayed towards
both PCTAIRE-tide and CDK substrate peptide. As shown in Fig. 2D,
PCTAIRE-1 activity determined using PCTAIRE-tide was signiﬁcantly
higher (~10-fold) thanusing CDK substrate peptide. To rule out thepos-
sibility that the obtained kinase activity was derived from non-speciﬁc
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TPKAA Neg Neg
TPKEA Neg Neg
0
50
100
150
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350
GST-PCTAIRE-1
SPDKM
SPKKM
SPKAM
SPKAR
[Substrate]/µM
0 1 2 3 4
Peptide Vmax (mU.mg-1) Km (µM)
SPKAR 350 ± 14 17 ± 2
SPKKM 240 ± 9.9 23 ± 2.6
SPKAM No fit No fit
SPDKM 34 ± 4 15 ± 6
PKXXXXXKKL PKXXXXXKKL
FIKICXXXXXIGRRR
Fig. 2. Optimisation of PCTAIRE-1 substrate peptide. The in vitro phosphotransferase activity of 1 μg GST–PCTAIRE-1 (A) and 10 ng CDK2–cyclin A2 (B) was determined using a
panel of CDK-tide derivatives (modiﬁcations from the parental peptide are underlined). Peptide conc. was varied over the range 0>100 μM and substrate saturation curves
were ﬁtted by non-linear regression to the Michaelis–Menten model. Fitted parameters [Km (μM) and Vmax (mU mg−1)] are listed in the adjoining table. (C) Based on the
CDK-tide optimisation, derivatives of NSF-tide were synthesised (modiﬁcations underlined) and assayed for PCTAIRE-1 activity as described in (A+B). 100% GST–PCTAIRE-1=
164 mU mg−1 and 100% CDK2–cyclin Y=940 U mg−1. (D) PCTAIRE-1 was immunoprecipitated from 2 mg of HEK293 lysate and kinase activity determined using 250 μM
CDK-tide or the optimised substrate, PKS*PKARKKL (PCTAIRE-tide) as described in Materials and methods. Results are expressed as mean±SEM and are representative of 3 inde-
pendent experiments.
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non-speciﬁc/generic IgG control, which showed negligible kinase activ-
ity (Fig. 2D). A recent study has described that endogenous PCTAIRE-1
activity was undetectable after its immunoprecipitation from HEK293
cell extracts, thus concluded it is “inactive” (data not presented) [12].
It is highly likely that their assays using MBP as substrate were too in-
sensitive to detect PCTAIRE-1 activity reliably.
3.5. Tissue expression and activity of PCTAIRE-1
After establishing a robust activity assay for PCTAIRE-1, we wished
to characterise its expression and activity in different tissues. A panel
of mouse tissue lysates as well as extracts from HEK293 cells were
immunoblotted using two different PCTAIRE-1 antibodies, one raised
against the N-terminal and the other against the C-terminal region of
PCTAIRE-1. Fig. 3A conﬁrms previous reports showing that PCTAIRE-1is highly expressed in brain and testis [7,8]. We also observed that
PCTAIRE-1 was expressed at low levels in skeletal muscle, heart, adi-
pose, lung and pancreas extracts, whereas it was not detectable
in liver, spleen and kidney extracts. Interestingly, we found that
PCTAIRE-1expression is relatively high in HEK293 cells. Two PCTAIRE-1
antibodies produced very similar proﬁles in terms of tissue distri-
bution, band intensity and pattern of band migration. We next
immunoprecipitated endogenous PCTAIRE-1 from the indicated tissue
lysates and immunoprecipitants were either used for immunoblotting
or assayed for kinase activity using PCTAIRE-tide (Fig. 3B). Generic IgG
was used as a negative control. The activity of PCTAIRE-1 was indeed
highest in brain and testis [7,12], with no or negligible activity detected
from all other tissues (Fig. 3B). The activity data correlated well with
immunoblots of precipitated PCTAIRE-1 (Fig. 3B), which corroborated
the blots of crude lysate in Fig. 3A. Others have reported that a
high-salt wash (0.5 M NaCl) signiﬁcantly reduced the activity of
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Fig. 3. PCTAIRE-1 is most abundant and active in mouse brain and testis. (A) Tissue homogenates were prepared from organs harvested from C57BL/6J mice. Laemmli extracts
(40 μg) were separated by SDS-PAGE and immunoblotted using antibodies raised against the N-terminus (G6.1) or C-terminus (C-16) of human PCTAIRE-1. HEK293 was included
as a positive control. (B) PCTAIRE-1 was immunoprecipitated from 2 mg of tissue lysate with anti-PCTAIRE G6.1 or rabbit IgG and assayed for kinase activity using 50 μM
PCTAIRE-tide. Results are expressed as mean±SEM and are representative of 3 independent experiments.
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frombrain or testis lysate and proposed the existence of a salt-labile fac-
tor(s) that inﬂuences PCTAIRE-1 activity [7]. However, in our hands, in-
creasing the ionic strength of the wash buffer (0.15 vs. 0.5 M) did not
affect PCTAIRE-1 activity when assayed with PCTAIRE-tide (data not
shown). It is possible that this “salt-labile factor” was merely a
non-speciﬁc contaminating kinase (or kinases) removed by a washing
buffer containing 0.5 M NaCl.
3.6. Cyclin Y binds to PCTAIRE-1 and robustly enhances PCTAIRE-1
activity
Recent studies showed that the C. elegans homologue of PCTAIRE-1,
PCT1, bound to CYY1, the C. elegans homologue of cyclin Y when
co-transfected in HEK293 cells [17]. We sought to determine if
mammalian endogenous PCTAIRE-1 interacts with cyclin Y. We
immunoprecipitated PCTAIRE-1 from brain and testis extracts and the
eluted proteins were immunoblotted with either anti-PCTAIRE-1 or
anti-cyclin Y antibody (Fig. 4A, upper panel). Indeed, cyclin Ywas readily
detected in PCTAIRE-1 immunoprecipitates, but not in those precipitated
with generic IgG. The reciprocal immunoprecipitation further conﬁrmed
this interaction (Fig. 4A, lower panel). It can be noted that immunoblot-
ting of the supernatants (pre- and post-immunoprecipitation) revealed
a negligible depletion of cyclin Y after PCTAIRE-1 immunoprecipitation
(when PCTAIRE-1 was depleted >90%) and vice versa (Fig. 4A, input
lanes), suggesting that only a fraction of cyclin Y proteins bind to
PCTAIRE-1 (at least in brain and testis extracts from adult mice). How-
ever, we cannot rule out the possibility that cyclin Y has a relatively low
afﬁnity for PCTAIRE-1 and the complex dissociates during isolation from
the extracts.
Since it has not been determined if catalytic activity is required
for PCTAIRE-1 to bind cyclin Y, we next co-expressed FLAG-WT–PCTAIRE-1 or FLAG-KD–PCTAIRE-1 with HA-cyclin Y in HEK293 cells
and performed FLAG-/HA-pull-down experiments (Fig. 4B). These
experiments clearly veriﬁed cyclin Y binds PCTAIRE-1, but not to
FLAG-NUAK1 kinase (non-speciﬁc control). Notably, cyclin Y binds
to both FLAG-WT-PCTAIRE-1 and FLAG-KD–PCTAIRE-1, which
demonstrates that catalytic activity is not required for this interaction.
Previous studies have shown that cyclin Y is targeted to the plasma
membrane by N-terminal myristoylation and therefore an N-terminal
epitope tag on cyclin Y might affect efﬁcient or compartmentalised
binding [24]. We have performed additional co-immunoprecipitation
experiments in HEK293 cells co-transfected with untagged PCTAIRE-1
and untagged cyclin Y and observed similar results (data not shown).
Employing PCTAIRE-tide as substrate, a PCTAIRE-1 activity assay was
performed on the same samples and showed a vastly increased
(>100-fold) activity when co-expressed with cyclin Y (Fig. 4B). These
results suggest that cyclin Y binding to PCTAIRE-1 plays a critical role
in regulating PCTAIRE-1 activity.
We repeated the peptide library screen using this signiﬁcantly more
active FLAG- PCTAIRE-1/HA-cyclin Y complex isolated from HEK293
cells. The results (Fig. 4C) identiﬁed similar amino acid preferences as
in Fig. 1B. Because analysis of the PCTAIRE-1/cyclin Y complex required
much smaller amounts of kinase, the contaminating activity observed in
our previous analysis with the kinase inactive PCTAIRE-1was no longer
detectable. In addition, analysis of the complex revealed additional se-
lectivity for aliphatic residues at the +3 position. This additional prefer-
ence may be a result of an improved signal over background, or
alternatively could reﬂect the inﬂuence of the cyclin subunit on peptide
phosphorylation speciﬁcity. Notably, a similar enhanced preference for
aliphatic residues at the +3 position has been observed for the yeast
CDK Pho85 speciﬁcally when complexed to the Pho80 cyclin and has
been attributed to direct interaction between the peptide and cyclin
[25].
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Fig. 4. Cyclin Y binds PCTAIRE-1 and robustly enhances kinase activity. (A, upper panel) PCTAIRE-1 was immunoprecipitated from 1 mg mouse brain or testis lysate using
anti-PCTAIRE-1 G6.1 or rabbit IgG and immunoblotted for PCTAIRE-1 and cyclin Y. Pre- and post-immunoprecipitation lysate for both tissues (representing 2% total input material)
was analysed in parallel to demonstrate the efﬁciency. (A, lower panel) Alternatively, brain/testis lysate was immunoprecipitated with anti-cyclin Y and blotted as described above.
(B) HEK293 were transfected with the indicated pCMV FLAG–PCTAIRE-1 and pCMV HA-cyclin Y constructs. pCMV FLAG-NUAK1 was included as a negative control. Cells were
harvested and exogenous PCTAIRE-1/NUAK1 and cyclin Y isolated by immunoprecipitation with FLAG- or HA-agarose respectively. Samples were immunoblotted with the indicated
antibodies or assayed for kinase activity using 50 μM PCTAIRE-tide. (C) The PSPL screen was repeated using PCTAIRE-1–cyclin Y complex prepared by co-expression of FLAG–PCTAIRE-1
and HA-cyclin Y in HEK293 and puriﬁed using FLAG-agarose. Results are expressed as mean±SEM and are representative of 3 independent experiments.
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To understand the molecular mechanism by which PCTAIRE-1 and
cyclin Y interact, we used the crystal structure of CDK2–cyclin A2
complex [4] as a model. Cyclin A2 activates CDK2 by stabilising
helix αC and the phosphorylated activation segment that ultimately
leads to a productive conformation of a kinase domain [4,26,27]. We
analysed the crystal structure of PCTAIRE-1 available from the Protein
Databank (PDB ID: 3MTL; Structural Genomics Consortium, June
2010). In contrast to the CDK2 kinase domain, which in the presence
of cyclin A2 is in the “closed” active conformation, the PCTAIRE-1 kinase
domain adopts an “open” inactive conformation with an unstructured
activation segment and αC helix (Fig. 5A and B). This suggests that a
binding partner may be required to stabilise the conformation of helix
αC and promote a “closed” active PCTAIRE-1 conformation. Since in
CDK2 and other CDK family kinases [28–30], this key activatory function
is fulﬁlled by cyclin molecules that bind and stabilise the αC helix and
activation segment (Fig. 5C), we hypothesised that cyclin Y binds and
activates PCTAIRE-1 in a way similar to which cyclin A2 binds and acti-
vates CDK2. To test this hypothesis we used the CDK2–cyclin A2 crystal
structure (PDB ID: 1FIN) as a guide to designmutagenesis of interacting
residues that would be predicted to disrupt PCTAIRE-1–cyclin Y bind-
ing. We looked for cyclin A2 residues that are important for the
CDK2–cyclin A2 interaction, and are highly conserved positions be-
tween cyclin A2 and cyclin Y (Supplementary Fig. 1). We also ensured
that these residueswere conserved in cyclin Y genes fromdifferent spe-
cies (Supplementary Fig. 1). Two residues fulﬁlled our criteria, Lys266
and Glu295 of cyclin A2 (Fig. 5D), which correspond to residues
Lys225 and Glu253 of cyclin Y (Supplementary Fig. 1). This Lys–Glu
pair forms key hydrogen bonding interactions with backbone atoms of
the loop immediately preceding the PSTAIRE helix of CDK2 (Fig. 5D).
Importantly, these two residue positions are also conserved in the inter-
actions between CDK2–cyclin B [28], CDK2–cyclin E1 [29], CDK9-cyclin
T1 [30], CDK4-cyclin D3 [31,32], CDK6-(viral)-cyclin [33], andPho85-Pho80 (yeast CDK-cyclin pair; [25]) (Supplementary Fig. 2). The
high level of conservation across different CDK and cyclin molecules
suggests that the Lys–Glu pair may also fulﬁl the same role in the
PCTAIRE-1–cyclin Y interaction. To test this idea, we mutated the Lys–
Glu pair residues and checked if this affected the ability of cyclin Y to
bind and activate PCTAIRE-1 (Fig. 5E and F). WT or mutant (K225A or
E253R) HA-cyclin Y was transfected alone or co-transfected with
WT-FLAG–PCTAIRE-1 in HEK293 cells. As illustrated in Fig. 5E,
expression of cyclin Y was comparable to that of WT and expression of
PCTAIRE-1was not affected by co-expression of cyclin YWT ormutants.
We observed that a cyclin Y Lys225Ala mutation completely abolished
the PCTAIRE-1–cyclin Y interaction and a Glu253Arg mutation severely
affected the ability of cyclin Y to bind PCTAIRE-1 (Fig. 5F). Consistent
with the general idea that cyclin binding is required for activation of
CDKs, and with our observations that cyclin Y is required for activating
PCTAIRE-1 over 100 fold (Fig. 4B), both cyclin Ymutants were incapable
of activating the PCTAIRE-1 kinase (Fig. 5F).
4. Discussion
By performing positional scanning peptide library analysis, we
have revealed key substrate-speciﬁcity requirements of PCTAIRE-1
(Figs. 1, 2 and 4C). Although the critical requirement for a proline
residue immediately C-terminal to the phosphoacceptor site (+1)
and preference of a basic residue (His, Lys or Arg) at +2 are similar
to other conventional CDK members, some elements were unique to
PCTAIRE. PCTAIRE-1 has a preference for phosphorylating Ser resi-
dues followed by a positively charged amino acid (Lys, Arg and His)
at the +4 position. We also found that PCTAIRE-1 prefers amino
acids with a small aliphatic side chain (e.g. Ala) rather than charged
residues at the +3 position. These analyses enabled us to generate
the PCTAIRE-tide peptide with the consensus sequence S-P-K/
R-ϕ-K/R/H (ϕ, small aliphatic amino acid), which we demonstrate is
an optimal substrate for measuring PCTAIRE-1 kinase activity.
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2093S.N. Shehata et al. / Cellular Signalling 24 (2012) 2085–2094Importantly, PCTAIRE-tide is a robustly improved PCTAIRE-1 sub-
strate when compared to the widely utilised generic protein kinase
substrates (MBP and histone H1) or CDK substrate peptide (Figs. 1A
and 2A). Currently, a major hurdle in studying PCTAIRE biological
functions is the inability to reliably detect speciﬁc kinase activity
from endogenous PCTAIRE-1 immunoprecipitates. We have over-
come this obstacle by using PCTAIRE-tide and were able to assay the
activity of endogenous PCTAIRE-1, with minimum or virtually no
background activity observed in the control immunoprecipitates
(Figs. 2D and 3B). A recent study described that PCTAIRE-1 activity
(measured in vitro using MBP as a substrate) was not detectable in
extracts of HEK293 cells after immunoprecipitation and the authors
concluded that PCTAIRE-1 is inactive in this cell line [12]. Consistent
with this ﬁnding, we observed that PCTAIRE-1 activity towards CDK sub-
strate was marginal and near background levels. By contrast, when
PCTAIRE-tide was used, PCTAIRE-1 activity was approximately 20-fold
higher than that detected using CDK peptide (Fig. 2D).
It has been reported that NSF can be phosphorylated by PCTAIRE-1
at a proline-directed serine residue on Ser569 in a cell-free assay [10],
although it was unknown how efﬁciently PCTAIRE-1 phosphorylated
NSF (as phosphorylation stoichiometry was not reported). Our analy-
sis showed that NSF-tide, developed from the surrounding sequence
of Ser569, is a very poor substrate for measuring PCTAIRE-1 kinase
activity (Fig. 2C). One of the key reasons for this is that PCTAIRE-1
(and also CDK1/2-cyclin complex [34]) cannot tolerate Asp at +2
(from Ser569) position (Fig. 2C). Therefore, it is questionable if NSF
is a bona ﬁde substrate of PCTAIRE-1. To validate NSF as a PCTAIRE-1
substrate, it would be important to observe site-speciﬁc phosphoryla-
tion (Ser569) of endogenous NSF in intact cells using PCTAIRE-1
knock-down/knock-out cells/tissues with or without an agonist/
antagonist (e.g. forskolin treatment which has been shown to inhibit
PCTAIRE-1 in HEK293 cells [6,12]).
CDK phosphorylation site preferences have been well established
by recent biochemical and structural studies [15,35,36]. The CDKs
show a strong preference for substrate peptides that contain a proline
at the P+1 position immediately C-terminus to the phosphorylation
residue (known as S/T-P motifs). Given the similarities in primary se-
quence and the fact that PCTAIRE-1 also prefers a proline at the +1
position it is possible the molecular basis for this requirement is
similar for PCTAIRE-1. However, CDKs can differ widely in conformation
(e.g. CDK4 [32]) and substrate speciﬁcity is determined by a range of
factors including CDK phosphorylation, substrate binding site confor-
mation as well as the type of cyclin bound (i.e. cyclin-mediated sub-
strate recruitment) [15]. To reveal the precise molecular basis for
substrate preference of PCTAIRE-1, it is necessary to have a detailed struc-
ture from a PCTAIRE-1–cyclin Y complex in the presence of PCTAIRE-tide.
PCTAIRE-1 shares a high percentage identity with other CDK fam-
ily kinases (e.g. 53.5% identity for PCTAIRE-1 and CDK2 kinase do-
mains) [3]. The crystal structure of PCTAIRE-1 kinase domain is
available from the protein databank (PDB ID: 3MTL). PCTAIRE-1 dis-
plays the typical kinase fold found in CDK2 and other eukaryotic pro-
tein kinases (Fig. 5A). Comparison of PCTAIRE-1 kinase domain
structure with the structure of CDK2 bound to cyclin A2 reveals two
important differences. The PCTAIRE-1 activation segment is unstruc-
tured and differs markedly from the position of the activation seg-
ment of CDK2 (Fig. 5A). Furthermore, the PCTAIRE-1 helix αC is
different from the so-called PSTAIRE helix of CDK2. In the case of
PCTAIRE-1, the region that generally folds into an alpha helix is in-
stead a short helix and consists largely of an unstructured loop (the
PCTAIRE loop; Fig. 5B). These analyses suggest that PCTAIRE-1 attains
the “open” conformation often seen in protein kinases that are inac-
tive and incapable of phosphorylating substrates [26,27]. By contrast,
the structure of CDK2 bound to cyclin A2 shows the “closed” active
conformation of CDK2 [4]. This suggests that the PCTAIRE-1 kinase
domain alone appears to be in an inactive and unproductive confor-
mation, and cyclin Y may be mimicking the role that cyclin A2 fulﬁlsin activating CDK2. To provide a model by which cyclin Y activates
PCTAIRE-1, we performed structural analysis followed by mutagene-
sis experiments. Here we have identiﬁed two cyclin residues (the
Lys–Glu pair) that bind backbone atoms from a loop that precedes
helix αC of CDKs. The position of this Lys–Glu pair and the interac-
tions these two residues make with CDKs (CDK2, CDK4, CDK6, CDK9
and Pho85), appear to be structurally conserved among ﬁve different
human cyclins (cyclin 2A, cyclin B1, cyclin D3, cyclin E1, cyclin T1), a
yeast cyclin (Pho80) and a viral cyclin (v-cyclin) molecule (Fig. 5C, D
and Supplementary Fig. 2). This conservation of the Lys–Glu pair is
quite remarkable given the diverse activation mode (at the molecular
level) of different CDKs by various cyclins. However, all cyclin mole-
cules share one common mechanism of binding through helix αC
and a loop preceding helix αC (Fig. 5C, D and Supplementary Fig.
2). The fact that the Lys–Glu pair makes contacts with backbone
atoms rather than speciﬁc amino acid side chains of CDKs may have
relieved these two residues from evolutionary pressures that have
resulted in the many different cyclin-CDK pair interactions. Mutation
of the same Lys–Glu pair in cyclin Y also disrupted PCTAIRE-1–cyclin
Y interaction, and as expected, these cyclin Y mutants failed to acti-
vate PCTAIRE-1 (Fig. 5E and F). Our data suggest that cyclin Y binds
and activates PCTAIRE-1 in a manner similar to which cyclin A2
binds and activates CDK2 (Fig. 5). However, it should be noted that
there are likely to be unique mechanisms by which PCTAIRE-1–
cyclin Y complex formation is controlled, including also the activation
segment phosphorylation of PCTAIRE-1. PCTAIRE-1 possesses a
unique N-terminal extension (~160 residues) and a short
C-terminal extension (~40–50 residues) prior to and following the ki-
nase domain, respectively [3]. Recently, Mikolcevic et al. showed that
PCTAIRE-1 mutants lacking the N-terminal region (Δ1–157 or Δ1–
121) failed to interact with co-expressed cyclin Y in HEK293 cells
[12]. This suggests that, in contrast to other known CDK-cyclin pairs
such as CDK2–cyclin A2, the kinase domain of PCTAIRE-1 alone may
not be sufﬁcient to bind cyclin Y (at least when co-expressed in
cells). Mikolcevic et al. also reported that the phosphorylation of
Ser153 on PCTAIRE-1 plays an inhibitory role in binding to cyclin Y.
They showed that a Ser153Ala mutant exhibited increased binding to
cyclin Y, whereas enhanced Ser153 phosphorylation in response to
forskolin treatment (which is known to activate PKA via increasing in-
tracellular cAMP levels) was associated with a decrease in PCTAIRE-1–
cyclin Y complex formation in HEK293 cells [12]. Another possibility is
that the formation of PCTAIRE-1–cyclin Y complex could be inﬂuenced
by other previously identiﬁed PCTAIRE-1 binding proteins, such as
p35 or p11 (reviewed in [3]). In order to form a clear picture of the
mechanism by which cyclin Y binds and activates PCTAIRE-1, again, it
would be necessary to obtain a crystal structure of PCTAIRE-1–cyclin Y
complex.
Analysis of endogenous PCTAIRE-1 kinase activity and PCTAIRE-1–
cyclin Y interaction in tissue extracts from adult male C57BL/6J mice
revealed that only a small proportion of total cyclin Y binds to
PCTAIRE-1 (at least in brain and testis extracts) (Fig. 5A). It is unknown
if this is because a major pool of cyclin Y binds to PFTAIRE-1 [24] or
other proteins. Alternatively, it is possible that the PCTAIRE-1–cyclin Y
complex is formed under particular conditions (during different stages
of development, cell cycle, stimulation/inhibition by various factors).
We also noted that although endogenous PCTAIRE-1 expression in
HEK293 cells was comparable to brain and testis (Fig. 3A), the activity
of PCTAIRE-1was signiﬁcantly lower in HEK293 cells. This could be pos-
sibly due to negligible or non-detectable amount of cyclin Y bound to
PCTAIRE-1 in these cells [12].
In conclusion,we have performedbiochemical analysis of PCTAIRE-1
substrate speciﬁcity and developed a signiﬁcantly improved assay to
assess PCTAIRE-1 activity employing PCTAIRE-tide. PCTAIRE-tide will
become a powerful tool in assessing endogenous PCTAIRE-1 in cells/
tissues in various biological contexts (e.g. during development, cell
cycle), and in response to extracellular agonists, as well as antagonists,
2094 S.N. Shehata et al. / Cellular Signalling 24 (2012) 2085–2094which would facilitate understanding the regulation and function of
PCTAIRE-1. Moreover, PCTAIRE-tide would be a useful tool to study
the regulation and function of PCTAIRE-2 and ‐3 isoforms. It is possible
that knowledge of the substrate speciﬁcity of PCTAIRE-1may facilitate
the in-silico identiﬁcation of PCTAIRE-1 substrates and/or potential
phosphorylation sites within putative substrates. We have also shed
light into the molecular basis of PCTAIRE-1–cyclin Y interaction and
provide a model by which cyclin Y activates PCTAIRE-1. Our structural
analysis and mutagenesis data suggest that cyclin Y binds and acti-
vates PCTAIRE-1 in an analogous manner to which cyclin A2 binds
and activates CDK2.
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